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Development of CXCR4 Inhibitors for Topical Treatment of Psoriasis 
Suthida Boonsith, Ph.D. 
University of Nebraska Medical Center, 2017 
Supervisor: David Oupický, Ph.D. 
Psoriasis is a chronic inflammatory skin disease that is often associated with 
systemic comorbidities and impaired skin barrier function. There are several treatment 
options including topical treatment with immunosuppressants, phototherapy, and systemic 
therapies using small molecules and biological agents. However, none of them can be 
regarded as a perfect solution due to their toxicity during chronic use. Recently, the 
CXCR4/SDF-1 axis was found to play an important role in the pathogenesis of psoriasis. 
AMD3100, a small molecule CXCR4 antagonist can selectively bind to CXCR4 and inhibit 
skin inflammation, reduce angiogenesis and infiltration of inflammatory cells. 
Unfortunately, AMD3100 can only be administered systemically. 
In this study, we aimed to develop CXCR4 inhibitor that can be applied topically in 
psoriasis as a way of reducing overall systemic toxicity of CXCR4 inhibition. We developed 
PAMD, a polycation based on AMD3100, as a topical drug to treat psoriasis. PAMD offers 
a great platform for chemical modification, drug combination, and the ability to form 
nanocarriers. Psoriasis is a skin disease therefore, it is desirable to deliver PAMD via a 
topical route to target the disease locally and improve safety and patient compliance. 
Stratum corneum (SC) is the foremost layer of skin, which acts as the main barrier to 
protect internal organs and limit the delivery of most drug molecules. Various attempts 
have been reported to increase skin penetration, including both passive and active 
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methods. The mechanism of skin absorption is dependent on size, charge, and partition 
coefficients of the penetrant. Based on previous reports on the role of hydrophobicity and 
charge on skin penetration of polymers, our approach relied on modifying the PAMD with 
citraconic anhydride for a negative charge and oleic acid for lipophilicity. 
The best performing negatively charged PAMD demonstrated low toxicity in 
HaCaT cells in vitro, and high retention and deep penetration in both healthy and psoriatic 
skin models. The favorable level of penetration may be due to the acidic skin environment 
and the intercellular transportation within SC, facilitated by the attraction of the polymer 
and diffusion respectively. IMQ-induced psoriasis mouse model was attenuated by a 
topical application of PAMD, PAMD.COO-, and subcutaneous injection of AMD3100. This 
observation provided evidence supporting that blockade of CXCR4/SDF-1 cascade 
reduces skin inflammation related to the decreased mRNA levels of pro-inflammatory 
cytokines IL-1β, IL-6, and TNF-α. The topical application of CXCR4 antagonistic polymers 
exhibited comparable in vivo therapeutic effects as systemic administration of AMD3100. 
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1.1 Skin Physiology 
Skin is the largest organ in the body and functions as a protective barrier. Skin is 
divided into three main layers: epidermis, dermis, and subcutaneous tissue (hypodermis). 
Epidermis consists of two distinct parts: the viable epidermis (70% water), and the stratum 
corneum (SC) (13% water) (Fig 1.1).  
SC plays a crucial role in maintaining a physical barrier and functions to prevent 
water loss and foreign substance penetration. Due to the highly lipophilic nature of SC, 
hydrophobic substances can easily enter the SC, but not viable epidermis. SC is 
approximately 10-20 μm thick, made of dead cells (corneocytes) filled with keratin, and 
embedded in tightly arranged lipid bilayers. The intercellular lipids are made of long chain 
ceramides, free fatty acids, triglycerides, cholesterol, and sterol/wax esters.  
Epidermis is composed of 10-20 layers of cells, mainly keratinocytes, and some 
dendritic antigen presenting cells named Langerhans cells (LCs). Keratinocytes are in the 
stratum basale and continuously divide to produce new cells. The new keratinocytes move 
to the upper layer, transition to corneocytes that have lost their nuclei, and eventually shed 
from the SC.  
Dermis is largely composed of collagenous connective tissue, blood vessels, 
nerves, several immune cell types, and appendages (hair follicles, sweat glands, and 
sebaceous glands). The dermis provides most of the skin’s mechanical resistance and 





Fig 1.1 Skin physiology and histology. Skin is composed of three layers: epidermis (50-
100 μm), dermis (1-2 mm), and hypodermis (1-2 mm). Adapted from [3] 
Drugs can be delivered to the skin for the treatment of skin diseases or through 
the skin for the treatment of systemic diseases. Viable epidermis is a common target site 
for anti-inflammatory agents, antiproliferative agents, vaccines, and experimental gene 
therapy due to the abundance of keratinocytes and dendritic cells. Dermis is also the target 
site for local anesthesia, analgesics, and drugs that need systemic absorption since this 








1.2 Psoriasis pathology 
Psoriasis is a chronic inflammatory skin disease that affects all ages and sexes. 
The prevalence in different populations varies from 0.09% to 5.1% [4] or approximately 
2% to 5% of the world’s population [5]. Psoriasis is likely the most prevalent immune-
mediated skin disease in humans. The cause of psoriasis is not well understood, but there 
are several factors that contribute to the initiation phase of the disease, including heredity, 
injury and trauma, infection, stress, environment, and medications. The major clinical 
manifestations of psoriasis include characteristic skin lesions, including chronic plaque (or 
psoriasis vulgaris), guttate psoriasis, and generalized or localized (pustular) psoriasis. The 
chronic plaque is the most common subtype and can involve multiple areas of the body 
[6]. 
Psoriasis is characterized by hyperproliferative keratinocytes in the interfollicular 
epidermis, along with abnormal terminal differentiation, dilation, hyperplastic blood 
vessels, and inflammatory infiltration of leukocytes into the dermis. The skin psoriatic 
patches are typically red, itchy, and scaly. The maturation of keratinocytes from basal layer 
to cornified layer in normal skin usually takes 28-30 days. In psoriatic lesions, the 
maturation is shortened to 3-5 days [7]. This shortened maturation is associated with 
massively disrupted terminal differentiation of keratinocytes and the retention of partially 
differentiated keratinocytes that cause the appearance of parakeratosis. Numerous 
proteins are down-regulated in these lesions, including keratin 1 and 10, which are 






Massive infiltration of inflammatory cells, dendritic cells and T cells are observed 
in psoriatic lesions. Numerous T cell phenotypes, for instance, CD4 (in dermis) and CD8 
(in epidermis) have been identified in varying amounts [9]. The vascular endothelial growth 
factor (VEGF), a major driver of inflammation-induced angiogenesis, is upregulated in 
lesioned epidermis and plasma of psoriasis patients and its levels correlate with disease 
severity. The greater the number of dilated dermal blood vessels the greater erythema 
exhibited in psoriasis [10]. 
The classic histological features of psoriasis are demonstrated by hematoxylin and 
eosin (H&E) staining (Fig 1.2) The epidermis is greatly thickened (acanthosis) with 
elongation of the rete ridges as keratinocytes hyperproliferate and quickly move through 
the epidermis. There is an increased SC hyperkeratosis with keratinocyte nuclei retention 
(parakeratosis). The retention of keratinocyte nuclei in the SC is due to the abnormal 
differentiation of skin cells. Infiltrated neutrophils are observed in the epidermis and form 
collections called Munro’s microabscesses. Then in the dermis, there is an abundance of 
inflammatory infiltrate consisting mainly of dendritic cells, macrophages, and T cells that 
consequently produce pro-inflammatory cytokines. 
  
Fig 1.2 Psoriatic lesion and histological features of human psoriatic skin [3] 
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1.3 Immune mechanisms in psoriasis 
The role of the immune system in psoriasis pathogenesis has been studied for 
several decades. The imbalanced interactions of innate and adaptive immune systems in 
the skin are believed to cause inflammatory skin conditions. Innate immune cells (dendritic 
cells, keratinocytes, macrophages, natural killer T-cells) induce a pro-inflammatory 
cytokine cascade that drives the adaptive immune response. Researchers have found a 
complex and long list of cytokines present within psoriatic plaques and the current focus 
is on TNF-α, IL-23, and IL-17. 
Dendritic cell (DC) subsets have been found in the epidermis (LCs) and dermis 
(dermal dendrocytes) of psoriatic lesions. LCs possess ATPase activity, that may play an 
anti-inflammatory role by degrading pro-inflammatory ATP [11]. In contrast, a reduced 
number of LCs are seen in the anti-TNF-α treated psoriatic lesions [12]. The plasmacytoid 
DCs produce high levels of IFN-α and can be activated by the TLR-7 agonist, Imiquimod 
[13]. IFN-α triggered psoriasis also supports the clinical observation that patients receiving 
IFN-α injections experience a flare up of psoriatic lesions at the site of injection [14]. The 
number of dendritic cells is increased in psoriasis plaques and can influence the behavior 
of T cells. DCs link innate and adaptive immune responses by acting as antigen presenting 
cells. The activated DCs in the skin secrete cytokine mediators such as IL-12 and IL-23 
that drive the differentiation of helper T cells into Type 1 (Th1) and Type 17 (Th17). Th1 
and Th17 released cytokines including IL-17 and IL-23. Then IL-23, IL-17, IL-22, IL-1β, IL-
6, and TNF-α interact as a network to activate keratinocyte and promote keratinocytes 
proliferation. 
The above set of observations defined the presence and significance of T cells in 
normal healthy skin as well as in pre-psoriatic skin. It has been estimated that there are 
approximately 2x1010 T cells in the entire skin surface or 1x106 T cells/cm2, which is twice 
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the total number of T cells in circulation. This understanding demonstrates that the large 
pool of T cells in the skin can initiate immune reaction without T cell recruitment from the 
blood [15]. The T cells appear to be pre-programmed with a Th1 cytokine secretion and 
create psoriatic lesions in immunodeficient mice [16].  
Th1 cells were originally considered to be the main mediator of immune response 
in psoriasis [17, 18]. The new paradigm form Th17 was recently discovered because of 
early clinical trial results indicating that the antibody which targets the p40 subunit can 
reduce psoriasis lesions [19]. The p40 subunit is shared by IL-12 and IL-23, which also 
have their own unique subunit p35 and p19 respectively. Evidence has shown increased 
levels of p19 and p40 mRNA in psoriatic lesions, despite no difference in p35 levels [20]. 
Therefore, IL-23 drives the pathogenesis of psoriasis. Th17 differentiation is dependent 
on IL-23 and crucial for the secretion of IL-17, IL-12, IL-22, and IL-9, which directly promote 
the inflammatory response of keratinocytes. As a result, IL-23 and Th17 were proposed 
as a new combination that drives immune activation and chronic inflammation [21]. IL-17 
is overexpressed in patients with a variety of allergic and autoimmune diseases and 
promotes the accumulation of neutrophils [22]. 
The relationship among T cell subsets and cytokines is demonstrated in Fig 1.3. 
Keratinocytes, NK T-cells, DCs, and macrophages are triggered by stimuli to produce 
cytokines that initiate DC activation. The activated DCs subsequently produce IL-12 and 
IL-23. IL-12 induces a Th1 immune response, characterized by the production of IFN-γ 
and TNF-α. Whereas IL-23 induces a Th17 immune response, characterized by the 
production of IL-17 and IL-22. These cytokines then promote the changes in epidermal 
keratinocytes, including the upregulation of pro-inflammatory cytokines, increases in 
mitotic activity of keratinocytes, production of growth factors that promote angiogenic 
response, and provide a positive feedback loop to macrophages. The crosstalk between 
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activated fibroblasts, infiltrating leukocytes, and epidermal keratinocytes enhances the 
inflammatory process and keratinocyte proliferation, and leads to the development of 
psoriasis. Macrophages can also be triggered by TNF-α to produce additional cytokines, 
which further stimulate dermal angiogenesis by promoting the migration, survival, and 
proliferation of endothelial cells, resulting in the formation of erythematous vascular 
plaques [23-25].  
 
Fig 1.3 Overview of potential interactions between immune effector cells, cytokines and 
pathways that contribute to the immunopathogenesis of psoriasis. The innate immune 
system provides an early-response mechanism against harm to the host. Dendritic cells 
bridge the gap between innate and adaptive immunity and induce the proliferation of T 




1.4 Psoriasis crosstalk 
Although psoriasis does not cause death, it does lead to a physiological burden 
and considerable psychological pain. Several studies showed the association of psoriasis 
with multi-system manifestations, including arthritis, Crohn’s disease, cardiovascular 
diseases [29, 30], depression, hyperlipidemia, type 2 diabetes mellitus, and obesity [31, 
32]. Moreover, some studies demonstrated psoriasis can increase the risk of death and it 
was highest for cardiovascular disease [33]. The relationship between psoriasis and 
systemic comorbidities is not fully understood but the sharing of inflammatory mediators 
may provide the link [34, 35]. 
It is important to note that skin diseases can also alter skin barrier integrity. In 
psoriasis, skin thickness is increased, especially in the epidermis layer and the impairment 
of the skin’s barrier function is well documented [36-39]. Ceramides, the main polar lipids 
in SC, were found to be decreased in lesioned skin of psoriatic patients [40]. The lower 
levels of ceramides were correlated with increased transepidermal water loss (TEWL) [41] 
and that contributed to the severity of psoriasis [42]. TEWL is an indicator of SC barrier 
function. The increase in TEWL indicates reduced water retention capacity and is 
characterized by abnormal cohesiveness and dryness. Furthermore, the disturbance of 
barrier integrity or function could initiate the cascade that subsequently triggers an 
inflammatory response in the dermis and leads to the development of psoriasis (Fig 1.4) 
[36], [43, 44]. Thus, a topical application of agents that can restore skin homeostasis could 
be useful for the prevention and treatment of skin disorders associated with permeability 




Fig 1.4 Psoriasis crosstalk; the occurrence of psoriasis, triggers the changes in skin 
structural and physiological functions. Far more than that, psoriasis is often present with 
inflammatory responses in other organs. Adapted from [37] 
  
Lipid contents  
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1.5 Treatment options 
In the late 1960s, psoriasis was thought to be caused by the abnormal proliferation 
of keratinocytes and subsequent differentiation. Thus, anti-proliferative agents such as 
methotrexate, anthralin, and coal tar were selected as treatments to inhibit keratinocyte 
proliferation. In addition, agents that can normalize abnormal growth and differentiation in 
keratinocytes, like vitamin D analogs and retinoids, have been used to restore epidermal 
homeostasis. Later in the late 1970s, a clinical observation was made that 
immunosuppressive agent cyclosporine A, which was primarily used as an anti-rejection 
drug in organ transplantations, unexpectedly cleared psoriatic lesions. Thus, the ultimate 
underlying cause of psoriasis has been attributed to a disorder of the immune system [46, 
47].  
Psoriasis plaques can persist for years if not treated and the disease is entirely 
reversible even after the appropriate therapy. According to the disease severity and 
response rate, there are a wide range of treatment options that can be applied to the 
affected area. Clinical classification of psoriasis ranges from mild (where less than 5% of 
the body’s surface area is affected), to moderate (5 – 10%), to severe (greater than 10%) 
[5]. The disease score can also be assessed by a trained healthcare practitioner using the 
Psoriasis Activity and Severity Index (PASI) score. This approach ranks the severity and 
area of erythema (redness), induration (thickness), and desquamation (scale) of the 
plaques in different body site. The treatment is considered successful if it shows 75% 
improvement from the baseline (reported as PASI75). 
It is highly recommended that patients with mild or moderate psoriasis use a topical 
treatment due to their low systemic toxicity and ability to target the affected area. 
Phototherapy is useful for patients with widespread disease who have moderate to severe 
psoriasis. Severe cases of psoriasis are often treated with systemic agents, but are 
11 
 
expensive and can be toxic. In many cases, systemic treatment and phototherapy are 
more effective options, but the duration of a treatment is restricted. For example, 
phototherapy may increase the risk of skin cancer [48], methotrexate can induce liver and 
bone marrow toxicity [49, 50].  
Topical therapy has been widely used in almost all psoriasis patients as a single 
or adjuvant therapy to reduce the amount of phototherapy or systemic treatments required 
to achieve satisfactory control, especially for moderate and severe conditions. Their 
convenience, safety, flexibility, efficacy, and low cost help to increase patients’ 
compliance. Moreover, topical drugs can be formulated into various forms such as 
powders, solutions, sprays, suspensions, emulsions, ointments, creams, pastes, gels, and 
patches. 
Several topical therapeutic agents are available for the treatment of psoriasis, but 
none of them can be regarded as an ideal drug. Topical corticosteroids demonstrate 
clinical improvement in various dermatoses including psoriasis and have been widely used 
for several decades, mainly due to their immunosuppressive, anti-inflammatory, and 
antiproliferative properties. However, a long-term and excessive use of topical 
corticosteroids can cause side effects and the efficacy of treatment can be reduced over 
time [51, 52]. Therefore, rotational therapy or an intermittent treatment schedule, are 
generally advised to improve the safety profile over longer periods and produce a 
satisfactory clinical outcome. 
Besides small molecule therapeutic agents, highly specific biologics have been 
developed to block T cell function at various steps, including preventing the activation and 
proliferation of T cells (alefacept), inhibiting lymphocyte activation and migration into 
inflamed tissues (efalizumab), and interfering with the binding of cytokines to their 
receptors expressed on immune cells (adalimumab) [23]. Although biologics lack the 
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adverse effects shown in some conventional therapies, they have their own set of side 
effects such as reactivation of latent infections.  
Current available treatment for psoriasis in enlisted in Table 1.1 
Table 1.1 Classification of psoriasis drugs in clinical uses 
Topical therapy
•Emollients,   Corticosteroids,   Retinoids,   Dithranol
•Ketatolytics (salicylic acid, urea),   Vitamin D analogues (calcitriol, calcipotriol)
•Calcineurin inhibitor (tacrolimus)
Phototherapy
•Narrowband UVA,    Broadband UVB,    Psoralen-UVA (PUVA)
Systemic therapy
•Metrotrexate, Cyclosporin A, Fumaric acid esters, Hydroxyurea
•Biological targeting molecules; anti-IL12/23 (Stelara, ustekinumab), 
anti-TNF (Humira, adalimumab), anti-IL17 (secukinumab)
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1.6 CXCR4/SDF1 axis in psoriasis 
CXCR4 is a highly conserved transmembrane G-protein coupled chemokine 
receptor that exclusively binds its ligand SDF-1. Stromal cell-derived factor 1 (SDF-1, or 
CXCR-12) has been found to have angiogenic activity and its primary receptor, CXCR4, 
is expressed by endothelial cells as well as monocytes and lymphocytes. The 
CXCR4/SDF-1 axis is usually involved in tumor progression, angiogenesis, metastasis, 
and survival [53]. SDF-1 functions as a chemotactic cytokine that direct the movement of 
circulating leukocytes to the sites of inflammation. The interaction between SDF-1 and 
CXCR4 causes the activation of various downstream signaling pathways and cytokine 
production. It is reported that AMD3100, a specific CXCR4 antagonist, can competitively 
bind to CXCR4, thus inhibiting the signaling cascades initiated by CXCR4/SDF-1 axis [54-
56]. 
In inflamed skin, CXCR4 is highly expressed on activated cutaneous DCs and 
SDF-1 is produced by the lymphatic vessels after antigen exposure. The inhibition of 
CXCR4 significantly impairs migration of cutaneous DCs and reduces contact 
hypersensitivity responses in mice [57].   
Silvana et al. found that there was an expression of CXCR4 cells in human 
psoriatic lesion and the upregulation of mRNA levels of CXCR4 and SDF-1 were found in 
both human psoriasis and experimental mouse models of chronic psoriasis-like skin 
inflammation (Fig 1.5). A systemic treatment with CXCR4 antagonist AMD3100 showed 
anti-inflammatory and anti-angiogenesis effects by CXCR4 blockade (Fig 1.6). AMD3100 
blocked the migration of CXCR4-expressing cells (T cells, DCs, and macrophages) into 
the inflamed area resulting in a reduction of epidermal thickness and dermal inflammatory 
infiltrates. In the K14.VEGF-A transgenic mouse model, VEGF-A expression was 
correlated to the severity of psoriatic condition and the CXCR4 receptors that were 
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expressed by cutaneous blood vessels. The blockade of CXCR4 reduced inflammation-
induced angiogenesis by lowering the number of blood vessels present in psoriatic lesions 
(Fig 1.7) [58].  





Fig 1.5 Up-regulation of CXCR4 and SDF-1 in psoriatic skin (1) Human (2) Imiquimod 
(IMQ) induced psoriasis mouse model, adapted from [58] 





Fig 1.6 Systemic treatment of psoriasis with AMD3100 lead to the reduction of (1) chronic 








Fig 1.7 CXCR4/SDF-1 axis in psoriasis. Circulating CXCR4 positive cells (leukocytes) are 
chemoattracted to the inflamed tissue by SDF-1. This attraction can be blocked by CXCR4 









1.7 Polymeric AMD3100 (PAMD) 
PAMD, a polymeric AMD3100, has been developed and is currently used as a 
gene delivery vector (polyplexes) for cancer cell invasion inhibition [59]. This polymer acts 
as an active drug and has the potential for chemical modification to control the efficacy 
and toxicity of the molecule [60, 61]. Chemical modification is possible because not all of 
the amine groups are required for the binding of CXCR4 receptor in order to exhibit 
pharmacological function and the overall charge can be reduced without compromising 
potency (Fig 1.8) [62].  
Synthetic polymers have been used for delivering therapeutic agents, including 
small molecules, proteins, and genes. The polymers can be fabricated into nanosized 
carrier and provide tunable chemical and physical features for controlled release, thereby 
improving the pharmacokinetics and pharmacodynamics of drugs [63, 64]. This potential 
offers a great platform to achieve effective drug delivery in the skin with PAMD. 
 
Fig 1.8 Structure of AMD3100 and PAMD. AMD3100 contains six secondary and two 
tertiary amines, providing the opportunity for chemical modification. 
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1.8 Topical drug delivery and penetration enhancement 
The administration of drugs to the skin has been practiced for centuries to treat 
local diseases. This route holds several advantages over other routes such as painless 
administration, avoidance of gastric degradation, and first-pass metabolism of drug 
molecules in addition to superior patient compliance. However, the major limitation of this 
route is that the skin is typically only permeable to small lipophilic drugs. The poor 
penetration of hydrophilic or charged molecules across the skin is primary due to the 
lipophilic nature of the SC and its low water content. 
The permeation of a drug through the SC is largely dependent on the partition 
coefficient of the drug molecule. Drugs that can passively move across skin typically have 
molecular weights less than 500 Da, Log P 1-3, aqueous solubility ≥ 1mg/ml, 
hydrodynamic radius ≤ 2 nm with a dose of approximately 10-40 mg/day. Ideally, a drug 
must possess both aqueous and lipid solubility. A highly hydrophilic drug will not be able 
to transfer into SC layer. In contrast, a highly lipophilic drug will form a depot in the SC 
layer [65]. 
The size and charge of drug molecules play an important role in percutaneous 
absorption. An increased molecular weight causes a decrease of the transport. The pH of 
the formulation is also an important factor that can influence the barrier properties of the 
skin, in addition to its influence on the ionic state of the drug. Enhanced percutaneous 
penetration was reported at pH lower than 4 and higher than 10 due to the extraction of 
the insoluble fraction of keratin. The electrical impedance of the skin was also decreased 
at pH lower than 3 and higher than 9 [66]. 
Most likely, skin diseases influence the cutaneous absorption of drugs. It has been 
reported that when the skin barrier is impaired, macromolecules can easily come into 
contact with keratinocytes and fibroblasts and increase cutaneous absorption [67-70]. 
18 
 
 Drug molecules can be transported into the skin by three different routes: 
intracellular (transcellular), intercellular, and follicular (hair follicles and sweat pores) (Fig 
1.9). Intracellular is the shortest route, but the drug must cross through both lipid structure 
and the cytoplasm of the dead keratinocytes which causes significant resistance to the 
permeation. The presence of appendages provides additional pathways even though it 
only accounts for 0.01% of the skin’s surface [71]. Recently, there is evidence showing 
that follicular penetration may be an important pathway for the penetration of topically 
applied chemicals [72, 73]. 
 
Fig 1.9 Drug penetration routes across SC. The penetration of drugs into the deeper 
regions of skin is controlled by the anatomical properties of skin (skin type and skin 
condition), drug features, and the formulation features. Adapted from [74] 
The successful topical application of therapeutic drugs depends on the permeation 
of drugs across the skin, reaching specific target tissues, and retaining therapeutic levels 
throughout the duration of use. Conventional transdermal delivery is generally limited by 
the barrier properties of the outermost skin layer. Several research groups have explored 
and examined various enhancement methods to overcome skin barrier and increase drug 
delivery into the skin. The transdermal drug delivery technology can be classified into two 
categories: passive and active methods. Passive methods include the utilization of 
chemical permeation enhancers and formulaic approaches. Meanwhile, active methods 
require an external source of energy to enhance skin permeability of the drugs [75]. 
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1.8.1 Chemical enhancement 
The passive penetration can be achieved by several compounds with a variety of 
enhancement mechanisms such as (1) increasing the interaction with polar head groups 
of lipids leading to packing lipid disturbance, (2) increasing water content between lipid 
bilayers (hydration), (3) increasing the drug solubility and the improvement of its partition 
coefficient, and (4) extraction of SC lipids. Ethanol is the most commonly used solution in 
transdermal formulations. Ethanol is capable of increasing the drug solubility and 
extracting skin lipids and proteins (increase the porosity of SC). Propylene glycol is the 
most frequently used co-solvent in dermatology and usually is combined with oleic acid 
for a greater penetration effect. Surfactants are used as emulsifiers to solubilize lipophilic 
drugs and SC lipid. The unsaturated fatty acids, especially oleic acid, has been described 
many times in the literature due to the potential to disturb the packing lipids in bilayers 
[76]. 
1.8.2 Nanocarriers 
Nanocarriers are another technology used to improve loading, protection, targeting 
and controlled release of therapeutic agents. In dermatological application, nanocarriers 
show properties that improve drug penetration across the SC at a reduced dose with few 
side effects [77]. Nanocarriers for skin application can be categorized into 3 main 
subtypes: lipid based systems, surfactant based systems, and polymer based systems 
(Fig 1.10).  
Lipid based nanoparticles are known for their excellent adhesion, skin hydration, 
and occlusion properties. The permeation through the skin is due to the flexibility of lipids 
that allows them to squeeze through SC channels. Liposomes are built from cholesterol 
and natural non-toxic phospholipids and therefore provide biodegradability, 
biocompatibility [78].  
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Surfactant based nanoparticles can be formulated with a wide variety of 
amphiphilic surfactant molecules that spontaneously aggregate in aqueous medium. 
Surfactants are characterized by hydrophilic heads and hydrophobic tails. Micelles are 
formed through the self-assembly of block copolymers and are widely used to encapsulate 
hydrophobic drugs to increase their solubility. 
Polymer based nanoparticles are colloidal carrier systems prepared from 
polymers. Polymer materials have been used for several aspects such as encapsulating 
active substances to improve their physiochemical characteristics, providing controlled 
release, and facilitating drug delivery through multiple administrative routes. Some of 
polymers are biodegradable and biocompatible, thus provide sustained drug release while 
minimizing skin irritation. The most commonly studied biodegradable polymers include 
poly-(lactic-co-glycolic acid) (PLGA) and poly(ɛ-caprolactone) (PCL). The polymeric 
nanoparticles are able to control drug release, increase drug adhesivity in the skin 
therefore becoming an important strategy to control drug delivery into the skin [79, 80].  
 

































































1.8.3 Physical enhancement 
Active methods to enhance skin delivery can be adopted when rapid drug action 
or macromolecular drug transportation are the main concern. This technique increases 
drug transportation through physical disruption of the skin barrier using various principles. 
Iontophoresis is a physical technique that applies a small electric current (0.5 
mA/cm2) to the skin, which provides the driving force needed for the penetration of 
substances. The transdermal transport is caused by direct electrophoresis and 
electroosmotic diffusion. The electrode with the same charge as the penetrant is placed 
above the drug reservoir and the repulsion of equally charged molecules facilitates the 
drug transportation [81, 82]. Electroporation uses a large voltage (50 – 1500 V) for a short 
period of 10 ms to 100 ms. The high current produces temporally pores where drugs can 
pass through [83]. 
Sonophoresis (phonophoresis) enhances transport of molecules under the 
influence of microwaves (300 MHz – 300 GHz) or ultrasound (20 kHz – 16 MHz). The 
enhanced percutaneous absorption of drug molecules is mediated by thermal and non-
thermal effects. Ultrasound-induced skin heating causes fluidization of SC lipids along with 
non-thermal effect by creating pressure variation in the SC surface or acoustic cavitation. 
Gas bubbles are formed and subsequently collapse, leading to the formation of holes in 
the corneocytes (enlargement of intercellular space) and disturbance of SC lipids [84]. 
Microneedles use a small needle (10 – 200 μm length and 10 – 50 μm width) 
connected to a drug reservoir and pierces the skin to deliver the drug. Microneedles 
enable drug delivery by different mechanisms: (1) forming micro-scale pores as a skin 
pretreatment, (2) coating drug onto the microneedle while the drug is dissolved off, (3) 
encapsulating drug within a microneedle made from water-soluble or biodegradable 
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Fig 1.11 Physical enhancement methods. Adapted from [75], [82], [86] 
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1.9 The effect of physiochemical characteristics of substance on skin delivery 
Polymers are becoming more common in the field of drug delivery. A large amount 
of literature has demonstrated the use of polymeric nanoparticles in topical treatment of 
dermatological diseases since the drugs are delivered directly into the skin. Various 
polymeric nanoparticles with optimal size, charge, and hydrophilicity have been designed 
to solve several limitations of topical drug delivery. 
  Roman et al. visualized the distribution of FITC-conjugated non-biodegradable 
polystyrene nanoparticles (diameters 20 and 200 nm) across porcine skin. They found 
that the nanoparticles preferentially accumulated in the hair follicles opening in a time-
dependent manner, while the smaller nanoparticles demonstrated highest accumulation 
[87]. Kohli et al.  investigated the skin penetration of fluorescence latex nanoparticles 
(diameter 50, 100, 200 and 500 nm) that were positively charged, negatively charged and 
neutral. They found that only 50 and 500 nm negatively charged particles could permeate 
the skin. It was believed that the penetration could be enhanced by the large surface of 
nanoparticles (small size) or high charge density (large size). Moreover, the repulsive 
forces between negatively charged skin lipids, proteins, and negatively charged particles 
may reach the threshold to allow temporary channels to open and permit the permeation 
through the skin [88, 89].  
Venuganti et al. investigated skin penetration of dendrimers and focused on the 
influence of dendrimer surface charge and dendrimer generation on skin permeation of 
5FU. They found that the drug penetration was enhanced with lower generation of 
positively charged dendrimers due to the reduction of skin resistance and interaction with 
skin lipid bilayers respectively. The concentration of dendrimers did not reflect the 
permeability of 5FU [90]. Yang et al. performed similar studies and found that the neutral 
and negative charged dendrimers increased skin permeation. Positive charged 
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dendrimers increased skin retention, but reduced skin permeation, whereas the 
conjugation with oleic acid increased skin absorption and retention. The difference of 
penetration may be because of skin-carrier interactions as well as other formulation 
ingredients and vehicles used [91]. 
Shah et a. evaluated the effect of oleic acid modified polymeric nanoparticles for 
the delivery of anti-inflammatory drugs. The in vitro skin permeation was performed and 
they observed high retention and increased skin penetration depth when nanoparticles 
were surface modified with oleic acid. These were explained by the positive charge of 
nanoparticles assisting the binding of SC; oleic acid hydrates skin and disturbs lipid 
bilayers of SC, thus facilitating the permeation of the drug into deeper layers of skin. The 
reduction of dermatitis response was enhanced by drug combination, nanoparticle 
formulation, and surface modification with oleic acid [92, 93]. 
A number of researchers investigated topical drug delivery in experimental 
psoriatic mouse model as well. Yin-Ku et al. evaluated the influence of psoriasis-like 
condition on the cutaneous permeation of four anti-psoriatic drugs (5-aminolevulinic acid, 
tacroimus, calcipotriol, and retinoic acid). They found that the most hydrophilic molecule 
showed the greatest skin deposition and flux, caused by the deficient resistance of 
epidermal barrier in psoriatic skin [94]. Sun et al. encapsulated curcumin into PLGA 
nanoparticles and tested it in a psoriasis mouse model. They found that nanoparticle 
carriers enhanced drug penetration and the smaller particles demonstrated higher 
penetration into psoriatic skin which significantly improved anti-psoriatic activity in mice 
[95].  
The enhancement of skin penetration using a pH-sensitive liposome was reported 
by Tokudome et al. The negatively charged liposome that was designed to be sensitive in 
acidic conditions (pH 5) increased skin delivery of hydrophilic drugs performed by vertical 
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diffusion cells. This was caused by the ability to fuse with cell membranes while the 
instability, in response to pH change, subsequently released the entrapped drug [96].  
 
1.10 Statement of the problem and the hypothesis 
Topical delivery of PAMD for the treatment of psoriasis 
This study served as an initial evaluation of polymeric AMD3100 (PAMD) drug that 
may be useful for a topical treatment of psoriasis. AMD3100 is a CXCR4 antagonist that 
blocks the inflammatory cascades associated with CXCR4/SDF-1 axis. The subcutaneous 
injection of AMD3100 demonstrated the reduction in psoriatic conditions related to skin 
inflammation and blood vessel angiogenesis. However, this route of administration 
generally causes pain and increases side effects related to systemic exposure. Hence, 
the topical application with PAMD might be a suitable approach due to several advantages 
including non-invasiveness of the procedure, expected long retention in the skin, the ability 
to deliver drugs to the diseased site, and minimization of systemic exposure.  
In this study, PAMD was delivered locally to the inflamed sites. PAMD is a synthetic 
cationic polymer that offers the full function of CXCR4 antagonism along with the 
properties to form a nanocarrier, the ability to combine with other drugs, and the ability to 
be custom-synthesized without compromising potency. PAMD used here is 
macromolecule with a molecular weight of 15 kDa, thus delivery into the skin is a 
challenge. It is well known that the charge, size, and hydrophobicity have a significant 
impact on skin penetration behavior. That being said, the existing publications are often 
contradictory. In addition to surface chemistry, psoriasis generally presents with 
compromised skin barrier function. Therefore providing the possibility for PAMD to reach 
the target tissue at a high concentration via topical administration.  
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To my knowledge, this is the first study that has demonstrated the effect of PAMD on 
psoriatic skin penetration and the in vivo efficacy compared to AMD3100 injectable form. 
The hypothesis of this study is: 
(1) The hydrophobicity and surface charge play an important role in skin penetration and 
influence on the anti-psoriatic activity of PAMD because of the differences in 
penetration depth and skin deposition and retention.  
(2) The topical formulation of PAMD or PAMD analog would provide a comparable or 
better in vivo therapeutic efficacy to AMD3100 injectable form. 
In the next chapters, I will present the modification and characterization of PAMD and 
PAMD analogs. The in vitro studies of polymers were performed in cell lines and Franz 
cells prior to the in vivo therapeutic study. Imiquimod-induced psoriasis in mice was used 




DESIGN AND SYNTHESIS 
 
2.1 Introduction 
In the previous chapter, I outlined the involvement of CXCR4 receptor and its 
ligand CXCL12 in psoriasis and how it had been studied and demonstrated to be 
upregulated in psoriatic lesions [58]. The inhibition of the axis using AMD3100 (S.C) 
accelerated the healing by reducing inflammation and angiogenesis. My lab has worked 
on PAMD for several years in regard to cancer therapy, but herein I would like to describe 
how PAMD, as a topical formulation, can be used as an anti-psoriatic drug for local 
treatment and long-term management.  
PAMD is a synthetic, cationic, and polymeric version of AMD3100 capable of 
acting as a non-viral gene vector and open to chemical modifications [97]. Furthermore, 
the polymer can condense negatively charged nucleic acids into nanosized particles 
through electrostatic interaction and facilitate the internalization across cell membranes. 
Once inside the cell, PAMD can also protect nucleic acids from nuclease degradation, 
thereby enhancing the therapeutic outcome of gene therapies. These qualities were 
demonstrated in an in vivo experimental mouse model that showed inhibition of cancer 
cell invasion with improved colloidal stability, survivability, and transfection activity. This 
shows the modified PAMD demonstrated dual functionality as an efficient gene delivery 
tool while maintaining CXCR4 inhibition [59-61]. 
While PAMD has been shown effective in previous use cases, its size makes 
penetrating the skin in a topical formulation a challenge. The focus of my study was to 
improve the skin penetration and retain CXCR4 antagonistic activity of PAMD that could 
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later translate into a topical formulation for psoriasis. Many research groups have tried to 
modify and formulate active macromolecular drugs for efficient dermal delivery. Their 
results suggest that the permeability coefficient of topically applied solutes is dependent 
on hydrophobicity, size, and charge [67, 91, 92, 98]. Therefore, this chapter focuses on 
the chemical modification of PAMD either by increasing content of hydrophobic moiety or 
negative charge.  
 
2.2 Materials and methods 
Materials 
N,N′-hexamethylenebisacrylamide (HMBA) was purchased from Polysciences, Inc. 
(Warrington, PA). Free-Base form of AMD3100 was purchased from Shanghai 
Biochempartner Co., Ltd (Shanghai, China). Rhodamine B Isothiocyanate, citraconic 
anhydride, oleic acid, A, N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride 
(EDC), N-hydroxysuccinimide (NHS) and 1-octanol were all obtained from Sigma-Aldrich 
(St. Louise, MO). Plasmid DNA (gWiz) was purchased from Aldevron (Fargo, ND). Human 
SDF-1α was from Shenandoah Biotechnology, Inc. (Warwick, PA). All other reagents and 
chemicals used in this study were obtained from Fisher Scientific (Waltham, MA) and used 







2.2.1 Synthesizing Polymeric AMD3100 (PAMD) and fluorescently labelling with 
Rhodamine Isothiocyanate (RITC) 
PAMD was synthesized by Michael polyaddition of equal molar ratio of AMD3100 
and HMBA according to Li et al. [59]. Michael addition reaction was described as a reaction 
between nucleophiles and activated alkenes. The reaction enables chain growth 
polymerization and has been employed in the synthesis of linear, graft, hyperbranched, 
and network polymers [99, 100]. 1 mmol of each reactant was dissolved in a glass 
scintillation vial containing 10 mL MeOH/water (7/3 v/v) mixture. Polymerization was 
carried out under nitrogen protection in dark at 37 °C for 3 days. Then, additional 0.1 mmol 
of AMD3100 was added to the reaction mixture and stirred overnight to consume any 
unreacted acrylamides. Product was purified by dialysis (MWCO 3,500) and dried in 
vacuum. To conjugate PAMD with RITC, RITC was first dissolved in DMSO and added to 
the PAMD solution dropwise under vigorous stirring at RT for 24 h. Unreacted RITC was 
removed by dialysis against deionized water for 3 days. The purified product was then 





Fig 2.1 Synthesis of PAMD and PAMD.RITC 
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2.2.2 Preparation of PAMD modified with citraconic anhydride (PAMD.COO-) 
The preparation was guided by the Hermanson group [101]. The compound 
citraconic anhydride was used to create a negatively charged PAMD because it is 
reversible after acylation. To synthesize PAMD.COO- with various degrees of citraconic 
anhydride substitution, PAMD was first dissolved in a 0.1 M sodium carbonate (pH 9) 
buffer. Then, 10 molar excess of citraconic anhydride to PAMD was added to the reaction. 
Multiple additions were done to maintain the solubility of the reagent by adding 1 M NaOH 
periodically to keep the pH in the proper range (8-9). Maintaining high pH is necessary 
due to the tendency of citraconylamides to hydrolyze at low pH. The reaction was 
performed overnight (12 h) at room temperature, purified by dialysis before lyophilization 
(Fig 2.2). To remove citraconic modifications and free the amine groups in PAMD, the pH 
of citraconylated molecules are adjusted to a lower pH (3-5). PAMD.COO- was dissolved 
in 0.1 M phosphate-citrate buffer and stirred at 37 °C for at least 24 h. 1H NMR and CXCR4 
redistribution assay were used to verify the reversal of PAMD.COO- into PAMD. 
 The negative-to-positive charge reversal is caused by a pH shift. Natural skin pH 
values are described in acidic range (4-7) [102] and the barrier disruption is associated 
with decreased pH value [94]. On this occasion, the cationic PAMD are first masked at the 
physiological pH, but once they are exposed to the intrinsic stimuli, the PAMD’s positive 
charge is recovered. The positive charge (amine group) is important for the receptor 




Fig 2.2 Synthesis and de-blocking amine groups of PAMD.COO- 
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2.2.3 Preparation of PAMD modified with oleic acid (PAMD.OA) 
 The penetration enhancers such as oleic acid (OA) appears to increase skin 
permeability, as a result from mechanisms involving both SC lipid fluidization and enhance 
permeant partitioning into SC lipid [103]. OA is a monounsaturated fatty acid and a 
component of natural fat derived from either vegetable oils or animal fat. OA has been a 
traditional (the most popular penetration enhancer) and widely studied fatty acid by the 
pharmaceutical industry as a vehicle for delivering actives through the skin [104]. 
The preparation of PAMD.OA was adapted from Park et al. [105]. EDC/NHS 
reaction was used to activate carboxyl groups in oleic acid and facilitate the conjugation 
with amine groups in PAMD. 70% ethanol was chosen because PAMD and OA are soluble 
in ethanol whereas EDC/NHS requires an aqueous solution. Thus, the co-solvent of 
ethanol and water can dissolve all reagents and allow the conjugation to proceed. To 
activate OA, 0.1 M NaOH was added to dissolve OA completely, followed by 2 molar 
excess of EDC and 2.5 molar excess of NHS. The reaction was stirred at 37 °C for 30 
min. In a separate vial, PAMD was dissolved in 70% ethanol mixed with 0.1 M NaOH. 
PAMD solution was poured into the activated oleic acid solution and stirred at 37 °C 
overnight (12 h). At the end of this reaction, the product was purified by dialysis and dried 
















2.3 Characterization of PAMD and PAMD analogs 
2.3.1.1 Proton nuclear magnetic resonance (1H NMR) 
The chemical structure of PAMD (Fig 2.4) conjugated with citraconic anhydride (Fig 2.5) 
and PAMD conjugated with OA (Fig 2.6) were confirmed by 1H NMR in DMSO (PAMD 
and PAMD-OA) and D2O (PAMD-COO-) using a Varian INOVA (500 MHz, Bruker BioSpin 
Corp., Billerica, MA). 
2.3.1.2 UV/Vis spectrophotometry 
The amount of RITC molecules per PAMD was calculated from UV/VIS measurement 
using Multi-Mode Microplate Reader (SpectraMax iD3, Molecular Devices, LLC, 
Sunnyvale, CA). Serial dilutions of RITC in 50% methanol-water were prepared and used 
to plot the standard curve. The polymers with unknown RITC conjugation were diluted with 
the same solvent and quantified using standard curve equation. 
2.3.1.3 Gel permeation chromatography (GPC) 
The molecular weight of PAMD was analyzed by GPC operated in 0.3 M sodium acetate 
buffer (pH 5) using Agilent 1260 infinity LC system equipped with a miniDAWN TREOS 
multi-angle light scattering (MALS) detector and a Optilab T-rEX refractive index detector 
from Wyatt Technology (Santa Barbara, CA). Polycation-compatible TSKgel 
G3000PWXL-CP column (Part No. 0021873, Tosoh Bioscience LLC, King of Prussia, PA) 
was used at a flow rate of 0.5 mL/min. The result was analyzed using Astra 6.1 software 
from Wyatt Technology. The molecular weight of PAMD analogs were calculated based 
on the determined molar mass of PAMD using GPC. The citraconic or oleic acid 





Fig 2.4 1H NMR characterization of PAMD.RITC. The aromatic protons (1-4) of AMD3100 





Fig 2.5 1H NMR characterization of PAMD.RITC.COO-. The content of citraconic 
anhydride substitution was determined from integral intensity of citraconic anhydride 





Fig 2.6 1H NMR characterization of PAMD.RITC.OA. The content of oleic acid was 
determined from integral intensity of oleic acid proton (5-6) at 5.3 ppm and aromatic 





Figure 2.7 Chromatogram of PAMD and PAMD.RITC expressed as a relative value to dRI 
and UV. The conjugation with RITC increased the size of PAMD as observed by the 
decreased retention time. The presence of RITC is confirmed by the positive UV 
absorbance signal in the chromatogram. 
40 
 









Mol of Oleate 
per PAMD3 
PAMD 18090 0.21 0 0 
PAMD.COO-.1 18770 0.05 1 0 
PAMD.COO-.2 20230 0.07 1.5 0 
PAMD.OA.1 18140 0.13 0 0.15 
PAMD.OA.2 19450 0.14 0 0.34 
1 Determined by GPC, 2 Determined by UV/VIS, 3 Determined by NMR 
*All polymers were RITC labelled, from now on I will use the word PAMD for PAMD.RITC, 














2.3.2 Partition coefficient determination 
The shake-flask method was used to measure partition coefficient of polymers. 
The equal volume of 1-octanol and PBS (pH 7.4) were mixed together and shaken for 24 
h at RT to mutually saturate two phases. The phases were allowed to separate overnight 
and were collected individually. The water-soluble polymers PAMD.COO- and PAMD were 
dissolved at a concentration of 1 mg/ml in PBS saturated 1-octanol and PAMD-OA was 
dissolved in 1-octanol saturated PBS. PBS and 1-octanol phase were mixed in 3 different 
ways (1:1, 2:1 and 1:2 (v/v)) in a separate tube. The tubes were placed on a shaker 
overnight and centrifuged at 1000 rpm for 5 min. The fluorescence of the PBS phase was 
read using Multi-Mode Microplate Reader (SpectraMax iD3, Molecular Devices, LLC, 
Sunnyvale, CA) at 515 nm excitation and 585 nm emission wavelengths. The amount of 
polymer in PBS phase was calculated based on the standard curve of fluorescent 
intensities versus serial dilutions of a polymer in PBS phase. The partition coefficient (P) 
is defined as [1-octanol]/[water] and usually given in the form of its logarithm to base 10 
(log P). Log P represents the affinity of a molecule for a lipophilic environment (Fig 2.8). 
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Fig 2.8 Partition coefficient of PAMD and PAMD analogs 
42 
 
2.3.3 DNA complexation assay 
Electrophoresis using low melting 0.8 % agarose gel was carried out to determine 
the feasibility of incorporation plasmid DNA into polymers. The successful condensation 
caused by the positively charged whereas negatively charged will not be able to complex 
with the DNA due to same charge repulsion. Polymer/DNA polyplexes were formed by 
mixing PBS (pH 7.4) solution of DNA and polymer at various polymer/DNA ratios (1 
corresponds to w/w of polymer per DNA of 1) to give a final DNA concentration of 20 ug/ml 
in polyplexes. The polyplexes were mixed by vigorous vortexing for 15 sed. followed by 
incubation at RT for 30 min. Polymer/DNA polyplexes were then loaded onto an agarose 
gel containing 0.5 ug/ml ethidium bromide and run under a constant voltage of 120 V in 
0.5X Tris/Borate/EDTA (TBE) buffer for 1 hr. The migration of DNA was visualized under 
UV transilluminator at a wavelength of 365 nm. The figure below demonstrated that only 
PAMD (2.5:1) and PAMD.OA (5:1) were complexed with DNA, presumably due to their 
positive rich charge. The greater amount of PAMD.OA was required for condensing the 
same amount of DNA, indicating the conjugation with oleic acid hindered the positive 
charge of PAMD. On the other hand, the modification with citraconic anhydride converted 
the charge to negative and unfolded DNA upon mixing (Fig 2.9). 
Fig 2.9 DNA Entrapment efficacy of PAMD and PAMD analogs in agarose gel 
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2.3.4 CXCR4 antagonistic activity 
CXCR4 antagonism of the polymers was determined by CXCR4 redistribution 
assay according to the manufacturer’s protocol [106]. The binding between CXCL12 and 
CXCR4 not only induces downstream signaling cascade but it also stimulates the 
endocytosis of the CXCR4 receptors. This assay monitors cellular translocation of GFP-
CXCR4 receptor in response to the stimulation with CXCL12. The CXCL12 stimulated cell 
was suggested by the internalization of GFP inside the cells (Fig 2.10). 
Recombinant human epithelial osteosarcoma U2OS cells stably expressing 
human CXCR4 receptor fused to the N-terminus of enhanced green fluorescent protein 
(EGFP) were purchased from Fisher Scientific. U2OS cells were cultured in DMEM 
supplemented with 2 mM L-Glutamine, 10% FBS, 1% Pen-Strep and 0.5 mg/ml G418 and 
seeded at a density of 8,000 cells/well in a 96-wells black plate with optical bottom. After 
24 h, cells were washed twice with 100 μL assay buffer (DMEM supplemented with 2 mM 
L-glutamine, 1% FBS, 1% Pen-Strep, and 10 mM HEPES) and incubated with serial 
dilutions of various polymers, or AMD3100 in the assay buffer containing 0.25% DMSO at 
37 °C for 30 min. Then, SDF-1 was added into each well to make a final concentration of 
approximately 10 nM and incubated for 1 hr. Cells were then fixed with 4% 
paraformaldehyde at RT for 20 min and washed 4X with PBS. The receptor internalization 
was measured using Cellomics ArrayScan VT1 Reader and SpotDetectorV3 BioApplication 
software (Thermo, USA). The percent of CXCR4 antagonistic activity was calculated 
relative to the positive (300 nM AMD3100) and negative (0.25% DMSO) controls, and the 







Fig 2.10 The internalization of receptors was induced by SDF-1 but inhibited by CXCR4 
antagonism compound. CXCR4 antagonistic activity was expressed by the reduction of 
green fluorescence signal 
 
 
Unstimulated cell: CXCR4-EGFP  
localized in the membrane 
Stimulated cell: CXCR4-EGFP  
is internalized in endosomes 
Inhibited cell: CXCR4-EGFP  






































Fig 2.11 CXCR4 antagonistic activity of PAMD and PAMD analogs 
CXCR4 antagonistic activity of PAMD was nearly 100% at the concentration as 
low as 0.5 ug/ml. The strong CXCR4 antagonistic properties observed in PAMD were 
caused by the specific electrostatic binding of positive charged PAMD to the negatively 
charged binding site of CXCR4 receptor. The conjugation with oleic acid reduced CXCR4 
antagonistic activity of polymers as the positive charge was neutralized, but the activity 
increased as the concentration increased. Meanwhile, the negative charge reduced 
CXCR4 antagonistic activity by losing its ability to competitively bind CXCR4 receptors 
with SDF-1 and was not concentration dependent (Fig 2.11).  
To prove the charge conversion properties of PAMD.COO- or the removal of 
citraconic groups. PAMD.COO- was incubated in 0.1 M phosphate citrate buffer pH 3, 4, 






Fig 2.12 1H NMR characterization and CXCR4 antagonist assay of PAMD.COO- at a 
different incubation time in 0.1 M phosphate citrate buffer (pH 3) 
The peak of citraconic anhydride proton (5.8 ppm) was reduced upon incubation 
time, along with the disappearance of green fluorescence in U2OS cell line (Fig 2.12). The 
results demonstrated the successful conversion of PAMD.COO- into PAMD in response 
to pH change. 
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Fig 2.13 CXCR4 antagonist activity of PAMD.COO- at different pH 
























Fig 2.14 Cytotoxicity of PAMD.COO- polymers in U2OS cell line 
CXCR4 antagonistic activities were tested from individual samples at a final PAMD 
content of 2 ug/ml. The above results indicated the conversion of PAMD.COO- into PAMD 
occurred in acidic condition (Fig 2.13) and the polymers expressed CXCR4 antagonistic 




IN VITRO CELL STUDIES OF PAMD AND PAMD ANALOGS 
 
3.1 Introduction 
The experimental models (cell lines, laboratory animals and three-dimensional 
skin model) let us imitate separate aspects of the pathological process under controlled 
conditions when studying psoriasis. This approach became irreplaceable in preclinical 
studies of new medicines, especially in drug screening. The use of established cell lines 
offers several advantages including low cost, readily availability in unlimited quantity, 
independence from donor variations, access to multiple passages, and cryopreservation. 
Moreover, the reproducibility and consistency allow us to identify variables and specific 
mechanisms that occur in primary cells. 
Psoriasis is a disease driven by the aberrant interactions between epithelium and 
the immune system. The proinflammatory cytokines, such as TNF-α, IFN-γ, and IL-17 
secreted by immune cells activate epidermal keratinocytes. The activation initiates 
changes in their terminal differentiation program and increase their proliferation rate. Anti-
psoriatic drugs can therefore target either the keratinocytes or the immunocytes.  
Keratinocyte proliferation is one of the hallmarks in psoriatic lesions and can be 
mimicked using the HaCaT cell line. HaCaT cells, the immortalized human keratinocytes, 
are often used as a cellular model for psoriasis [107, 108] and the compounds that inhibit 
keratinocyte proliferation potentially used as anti-psoriatic agents. HaCaT cells were 
developed from a long-term primary culture of adult human skin keratinocytes [109]. The 
cells are easily cultured, immortal (>140 passages), and do not require additional 
supplements such as growth factors in the culture medium. HaCaT cells are non-
49 
 
tumorigenic, so their transplantation to lab animals does not cause solid tumors, but they 
do exhibit parakeratosis (incomplete maturation of epidermal keratinocytes) which is one 
of the manifestations of psoriatic skin. These cells also differentiate normally and express 
common epidermal markers shown in vivo. However, HaCaT cells have some limitations, 
such as a decreased proliferation rate in response to TNF-α, IFN-γ, and IL-17 [110], which 
makes them unable to synthesize lipids that are necessary for proper skin barrier 
formation [111]. 
The HaCaT cell line is closely related to normal keratinocytes presented in skin 
and thus offer a suitable model to study regulatory mechanisms in the process of human 
epidermal cell differentiation and proliferation. In addition, HaCaT cells have been used in 
pharmacologic [112] and cutaneous toxicity studies [113, 114]. After keratinocytes are 
exposed to toxic compounds, they upregulate series of pro-inflammatory cytokines. These 
contribute to increased reactive oxygen species production and activate multiple 












3.2 Cell culture and cell viability determination 
3.2.1 Cell culture 
HaCaT cells, a spontaneously transformed human epithelial cell line from adult 
skin, were provided courtesy of Dr. Keith R. Johnson, Department of Biochemistry and 
molecular biology, UNMC. Cells were grown in tissue culture flask (75 cm2) at 37 °C under 
a humidified atmosphere of 95%CO2/5%O2. The cell growth medium comprised 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with L-glutamine, 10% FBS, 
and 1% antibiotic Penicillin-Streptomycin solution (penicillin 5000 U/ml and streptomycin 
0.1 mg/ml). The cells were harvested by trypsinization (5 min in 0.25% trypsin-EDTA) 
when reaching 80% confluency and sub-cultured every three days. 
 
3.2.2 Cell viability determination 
Cell toxicity of the polymers was evaluated by CellTiter-Blue® cell viability assay. 
HaCaT cells were seeded at a density of 8,000 cells/well in a 96-well plate. After 24 h, the 
medium was replaced by 150 μL serial dilutions of polymer in serum-containing medium 
before returning the cells to the incubator for 24 h. Polymer solutions were aspirated and 
replaced by a mixture of 100 μL serum-free media and 20 μL of CellTiter-Blue® reagent 
(CellTiter-Blue® cell viability assay, Promega) then incubated for 1 h. The fluorescence 
was read using spectraMax®M5e Multi-Mode Microplate Reader at 560 nm excitation and 
590 nm emission wavelength. The relative cell viability (%) was calculated as 
[F]sample/[F]untreated × 100%. The IC50 was calculated as polymer concentration 
causing 50% inhibition of cells growth relative to untreated cells using a built-in dose-

























































Fig 3.1 Cytotoxicity studies of polymers in HaCaT and U2OS cell lines. Each value is 
represented as mean ± SD (n=3) 
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Table 3.1 IC50 value of polymers using built-in curve fitting procedure in GraphPad Prism  
 PAMD PAMD.COO-.1 PAMD.COO-.2 PAMD.OA.1 PAMD.OA.2 
HaCaT 
(μg/ml) 
16.8 > 60 > 60 21.3 22.0 
U2OS 
(μg/ml) 
4.7 > 60 > 60 15.7 13.5 
 
Percentage cell viability was measured as shown in Fig 3.1 and the IC 50 values 
of polymers were calculated in Table 3.1. PAMD demonstrated the highest cell cytotoxicity 
in both HaCaT and U2OS cell lines. Whereas PAMD.COO- groups did not show the same 
level of cell killing activity when various of concentrations were tested, indicating their 
biocompatibility on tested cell lines. The keratinocytes toxicity was likely caused by the 
highly positive charge of PAMD, as the shielding of amine groups by oleic acid (PAMD.OA) 
decreased toxicity. Positively charged polymers demonstrated higher toxicity by 
enhancing cell internalization and disrupting membrane integrity [116, 117]. 
In many cases, higher cell killing activity is an evidence of the possibility to inhibit 
cell proliferation in psoriasis. But it also may demonstrate high cutaneous toxicity and 
promoting skin disease as well. So, doubt remains that PAMD’s exhibited toxicity or 
therapeutic effect is preferable for psoriatic skin. Similarly, the compound that does not 
appear to cause toxicity may not illustrate the potential for psoriasis management. 





The positively and negatively charged polymers were compared with AMD3100, a 
small molecule and active compound used for PAMD polymerization reaction. The 
following results indicated that cell toxicity was charge and size dependent (Fig 3.2). 
























Fig 3.2 Cytotoxicity of PAMD polymers in HaCaT cells. Each value is represented as mean 












3.3 Permeation of polymers through reconstructive human model 
The assessment of percutaneous absorption of molecules is an important step of 
topical drug development and should be done using standard experimental models for the 
prediction of successful skin delivery. Reconstituted human epidermal (RHE) model is 
recommended in OECD test guideline 428 (skin absorption: in vitro method) and served 
as a suitable model as an alternative to human skin for the assessment of skin permeation 
and penetration in vitro [118, 119]. RHE culture model is the growth of epidermal 
keratinocytes at an air-liquid interface. The keratinocytes can differentiate and stratify to 
mimic the morphology of normal epidermis. The use of RHE is a suitable method to 
minimize the variation between different skin samples. The similarity of tissue architecture 
and lipid composition to human skin offer the advantages in dermal penetration studies 
even though artificial skin tends to have higher penetration rate than original skin.  
EpiDerm™ permeation studies 
The EpiDerm™ skin model (EPI-212-X) was purchased from MatTek Corporation 
(Ashland, MA, USA) and used within 3 days of delivery. The tissue consists of normal, 
human-derived epidermal keratinocytes (NHEK) which have been cultured to form a 
multilayered, highly differentiated model of the human epidermis (7-10 cell layers, 75-100 
μm thick). The tissue was incubated for 1 hour at 37 °C supplied with 5% CO2 prior dosing 
with 200 μl of polymer solution (150 μg/ml). Tissue was incubated with polymer for 9 hours, 
washed with PBS, incubated in 10% Formalin for 20 min at room temperature, and washed 
again with PBS with gentle agitation. To image the penetration depth, the tissue insert was 
cut and mounted onto a confocal dish, placed top side of the tissue down on the glass. 
The penetration was imaged to a depth of 30 μm and the fluorescence intensity of each 
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Fig 3.3 Penetration of PAMD and PAMD analogs in Epiderm™ skin model 
 




































From the results, all polymers showed highest intensity at the depth of 10 μm, 
indicating they were collected in SC region (Fig 3.3). This skin model is a reconstruction 
of normal human epidermis and the permeation behavior was found to correlate with 
barrier function. The high molecular weight substances have difficulty penetrating the skin. 
Thus, without the damaged skin condition and the modification of molecules, these 
polymers will be restricted to SC layer and unable to affect the lower layers due to the 
tightly packed dead skin cells. However, it is difficult to conclude that PAMD penetrated to 
a higher degree than PAMD.COO- or PAMD.OA due to the fluorescent signal being 
unequal among the polymers (PAMD > PAMD.OA > PAMD.COO-) (Table 2.1), the same 
pattern was clearly observed in Fig 3.4. The deeper region might have PAMD.COO- but it 
was lower than the detection limit. 
 The in vitro percutaneous permeation studies using mouse skin would be a good 
alternative to human skin to observe the penetration behavior in healthy and psoriatic skin 
during the initial development of novel compounds. The animal model is more feasible, 
relatively low cost, readily available, and can resemble this disease. A wide range of 
animal models have been developed and optimized for testing skin absorption for skin 






EX VIVO SKIN PENETRATION STUDIES 
 
4.1 Introduction 
During the development of a suitable topical formulation, the most important 
parameter for characterizing penetration behavior is the diffusion profile of the active 
ingredient. The most frequently used diffusion device for evaluating cutaneous delivery of 
drugs ex vivo and in vivo is the franz cell (Fig 4.1).  
 
Fig 4.1 Franz cell used for the determination of skin penetration. It consists of two 
compartments: donor and receptor, between which the excised skin is mounted.  
 
4.2 Franz cell protocol 
The psoriatic skin-like mouse model was developed and used. Mice were shaved 
on their dorsal area (approx. 5 cm2) and treated with 65 mg of IMQ cream (Perrigo®) for 
10 days. Mice were then euthanized and the dorsal skin was collected. The skin was 
carefully examined for any defects and the fat and subcutaneous tissues were gently 
removed using a surgical scalpel. Afterward, the skin was wrapped with aluminum foil, 
sealed in a bag, stored at -20 °C, and used within 2 months.  
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The skin was thawed and washed with PBS (pH 7.4) prior to mounting on Franz 
diffusion cell set up (Permegear Inc., Riegelsville, PA). The SC side of the mouse skin that 
was exposed to polymer solution in the donor chamber was 0.64 cm2 and the receiver fluid 
volume was 5 ml. Each fluorescently labelled polymer was dissolved in ethanol and PBS 
50:50 (v/v) with a concentration of 7.5 mg/ml. 200 μl of polymer solution was added to the 
donor compartment and was covered with parafilm to prevent evaporation. The skin 
permeation study was performed using 3 diffusion cells. The receiver compartment was 
filled with PBS and stirred at 300 rpm. The temperature of receiver compartment was 
maintained at 37±0.5 °C to simulate the skin temperature at physiological level.  
4.2.1 Quantification of polymer skin deposition 
After 24 h of skin permeation, the entire dosing area (0.64 cm2) was collected with 
a biopsy punch. Each sample was carefully washed with 3X water followed by 3X ethanol 
to ensure the removal of the residual polymer from the skin surface and blotted dry with 
lint-free absorbent wipes (Kimwipe). The skin was subsequently cut into small pieces, 
added to 300 μl PBS containing 0.1% Tween 20 and homogenized using tissue lyser 
(TissueLyser II, QIAGEN) at a frequency of 30/s for 5 min. To this sample, 300 μl of ethanol 
was added to enhance polymer solubilization and sonicated using bath sonicator 
(Bransonic® CPX Ultrasonic Baths, Branson Ultrasonics Corp., Danbury, CT) for 1 h. The 
extracted samples were centrifuged at 12,000 rpm for 30 min and the supernatant were 
collected.  The fluorescence of the supernatant was analyzed using Multi-Mode Microplate 
Reader (SpectraMax iD3, Molecular Devices, LLC, Sunnyvale, CA) at 515 nm excitation 
and 585 nm emission wavelengths. The amount of polymer in the skin was then quantified 
based on a standard addition method. The known concentrations of polymer were added 
to the supernatant and a standard curve was generated of fluorescence intensities versus 
concentration of serial dilutions of polymer. All statistical analyses were performed using 
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GraphPad InStat (La Jolla, CA). A one-way ANOVA with Tukey-Kramer adjustment was 
used for multiple comparisons where appropriate in order to determine significant 
differences. 
Penetration amount (ug)







































































Fig 4.3 Increased penetration in psoriatic skin when compared with healthy skin 
Psoriatic condition enhanced the penetration of polymers (Fig 4.3). The negatively 










































































Fig 4.4 The effect of PAMD modification on skin penetration 
The SC layer is the outermost layer of skin and functions as a principal barrier to 
foreign substances. This barrier is compromised in psoriasis, causing increased skin 
permeation. SC is arranged in a brick and mortar like structure. In addition to keratin-rich 
corneocytes, the intercellular matrix is made of long chain ceramides, free fatty acids, 
triglycerides, and cholesterol. The lipids have a pKa between 4.8 and 6.3 and are 
responsible for the net charge of skin. The pH of healthy skin surface is generally acidic 
(pH 4-5) and it becomes even lower when psoriasis is formed (pH 3-4). At the low pH of 
psoriatic skin, the population of lipids in this region is ionized and has an increased positive 
charge, thus increasing the attraction of anionic molecules into the skin. Moreover, high 
TEWL was reported in psoriasis, indicating a reduced lipid content in the skin. These 
changes in the skin properties also facilitate the penetration of hydrophilic molecules into 
psoriatic skin. Epidermis is filled with corneocytes surrounded by aqueous pores and thus 
hydrophilic substances can freely move throughout this layer. Fig 4.4 demonstrates that 
the modification of PAMD changed skin penetration behavior, the penetrated amount was 
pronounced with hydrophilic, negatively charged PAMD. 
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4.2.2 Visualization of polymers penetration in skin 
Each skin sample was rinsed to remove excess polymer from the surface, 
embedded in a tissue freezing medium (OCT™ compound; Tissue-Tek®) and frozen 
overnight in a freezer (-20 °C). The frozen samples were sectioned to 10 μm thick slices 
using a cryostat (Leica Microtome, Leica Biosystems Inc., Illinois, USA). Skin sections 
were imaged using a fluorescent microscope, 10X objective and analyzed using ImageJ 
software. 
 According to the Fig 4.5, weak fluorescent signal was observed in healthy tissue 
due to poor penetration across skin barrier. Defective psoriatic skin enhanced the 
penetration of the polymers as indicated by a deeper fluorescent penetration signal. 
PAMD.COO- groups demonstrated strong fluorescent signal even though they contained 
the lowest amount of RITC, while the groups with the highest content of citraconic 
anhydride showed a noticeable amount of polymer in a dermal compartment. These 
results indicated negatively charged PAMD promoted greater retention and penetration 












Fig 4.5 Psoriasis caused weak organization of SC and leaded to the alteration of drug 
penetration behavior along with enhanced polymer permeability. 
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4.3 Penetration pathway study 
The embedded skin was cryosectioned to 10 μm and placed on glass slides. The 
slides were air dried, fixed by cold acetone for 5 min, and gently washed using deionized 
water. The skin strips were then treated with polymer solutions in a concentration of 1 
mg/ml at RT for 1 h. The excess polymer was washed with water and covered with a glass 
cover slip. The slides were visualized using a fluorescence microscope. 
 
Fig 4.6 Skin penetration pathway of polymers 
 Vehicle   PAMD                         PAMD.OA.1 
         PAMD.OA.2         PAMD.COO-.1    PAMD.COO-.2 
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As described above, there are several penetration routes through the SC. The 
internalization or strong interaction between polymer and skin cells lead the polymer to 
transport via the intracellular route. Meanwhile, the repulsion or less interaction with skin 
cells may facilitate the polymer to follow the intercellular route, thereby allowing rapid 
diffusion throughout the skin layers. Cell membranes consist of two sheets of 
phospholipids arranged tail to tail. The hydrophilic heads face outward and are abundant 
with phosphate groups making them negatively charged. The positively charged polymers 
(PAMD and PAMD.OA) preferentially transport via intracellular router due to a strong 
charge interactions with cells. In contrast, the negatively charged PAMD.COO- is likely to 
be transported via intercellular route because of the limited interactions of the polymer 
with the cells (Fig 4.6). 
 









PSORIASIS MOUSE MODEL 
 
5.1 Introduction 
Despite being common in humans, there still is a lack of a suitable animal model 
to study psoriasis pathogenesis. Anecdotal reports on spontaneously occurring psoriasis-
like conditions in monkeys, dogs, and pigs have been published [120], but these 
phenomena occurred randomly, therefore excluding them from systematic psoriasis 
research. In the past decades, publications of psoriasis animal models have increased 







Fig 5.1 Publications related to the pathogenesis and animal models of psoriasis show 
increased numbers during 1965 and 2007 [121]. 
Despite large investments in drug development, the overall success rate of drugs 
during clinical trials remain low. Currently, the development of a new drug takes 
approximately 20 years to the market and up to 90% of new compounds fail in clinical 
phases. The main reason for these failures is the lack of efficacy during phase II and III of 
clinical development, which depends on the selected animal model that allows the 
66 
 
therapeutic assessment of a specific compound [122]. This indicates a strong need for in 
vivo and in vitro models that are reliable, closely resemble human disease, and minimize 
time spent in a fiscal manner within the pharmaceutical industry in order to increase 
success rates for new drugs being approved. 
Mouse models are the most commonly used experimental animal model for 
studying human diseases, including psoriasis. Advantages such as controlled breeding 
and low costs allow researchers to easily engineer experiments that search for better 
treatments and understanding of the fundamental mechanisms of disease. However, there 
are several considerable anatomical and physiological differences between human and 
mouse, which may influence the phenotype and pathogenesis of disease. For skin, the 
epithelium of mice is composed of densely populated hair follicles, whereas human skin 
has a much greater interfollicular composition. Mouse epidermis is generally comprised of 
2–3 keratinocyte layers with thickness less than 25 μm. Human epidermis is much thicker 
(more than 50 μm) but shows slower epidermal turnover. Furthermore, mouse skin 
regenerates effectively without significant scarring [123]. 
The presence of certain types of immune cells causes the difference in antigen 
expression pattern and immune response. Mice have several different subtypes of 
dendritic cells (DCs) including CD8+ dendritic cells and other inflammatory cells such as 
dendritic epidermal T cells (DETCs) and NK 1.1+ T cells that are not found in humans (Fig 
5.2). Mice are also inbred, raised under controlled conditions, and genetic models are 







Fig 5.2 Skin structure in human and mice. The differences include the thickness of the 
epidermis, the density of hair follicles, the differential program of keratinocytes and the 
presence of immune cells [3]  
 
5.2 Animal models of psoriasis 
There are four main types of in vivo psoriasis animal models and they usually rely on mice 
as the host based on the following experimental settings. 
Table 5.1 Summary of experimental psoriasis mouse models (adapted from [120], [3, 
123-126]) 
1. Spontaneous mutation 
• 1. Flaky skin (fsn) 
• 2. Chronic proliferative dermatitis (cpd) 
• 3. Homozygous asebia (ab) 
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These animal models displayed some histological features of psoriasis such as 
epidermal thickening, increased dermal vascularity, and infiltration of mast cells and 
macrophages. However, the absence of epidermal T cell infiltrate rendered the 
immunosuppressive drug (Cyclosporine A), used to treat psoriasis, ineffective. Given 
this result, it appears that there is no immunological basis for psoriatic formation in 
these models. 
2. Genetically engineered  
3. 1. Transgenic; a genetic 
element has been 
introduced 
4. 2. Knockout; a genetic 
element has been 
removed 
• 1. Targeting immune system: K14.p40  
• 2. Targeting vascular endothelium: K14.VEGF 
• 3. Targeting epidermal keratinocytes  
1. 3.1 Overexpression of the cytokines of interest in the basal 
epidermal layer under the control of promoter keratin-5 (K5) 
and 14 (K14): K5.STAT3, K14.IL-6, and K14.TGF-α   
2. 3.2 Overexpression of the cytokines of interest in the 
supradermal epidermal layer under the control of promoter 
keratin-10 (K10) and involucrin (invol): K10.BMP-6, 
Invol.IFNᵧ, and Invol.β1-integrin 
• 4. JunB/c-Jun inducible epidermal deletion and IKK2 
knockout 
Many cytokines have been proposed to play crucial roles in the pathogenesis of 
psoriasis. These animal models are designed to modify cytokine expression through 
specific promoters, which helps to elucidate the role individual cytokines play in the 
pathogenic cascade of psoriasis and the subsequent in vivo effects.  
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Based on many observations, only a single cytokine is not sufficient to induce the 
complex changes seen in psoriasis. Thusly, it supports the concept of the cytokine 
network in psoriasis. The animal models in this group exhibit psoriatic mixed with non-
psoriatic features (alopecia and early lethality). 
1. Immunological transfer 
(Humanized) 
• 1. Human T cell transfer: transfer of CD4+/CD45RBhi into 
severe combined immunodeficient (scid) mice 
• 2. Human skin xenotransplantation: implantation of human 
psoriatic tissue onto scid mice 
These models highlight that psoriasis is an immunological disease mediated primarily 
by T-cells and not epidermal keratinocytes. To date, the xenograft model comes closest 
to human psoriasis in terms of genetic, phenotypic, and immunopathogenic processes. 
Despite that, the difficulties in obtaining human psoriatic skin limits the number of 
animal that can be widespread utilized. However, both models are usually employed 
for the evaluation of potential therapeutic agents due to human psoriatic drugs (both 
small molecules and biologics) demonstrating efficacy in these models. 
2. Direct induction 
• Injection of cytokines: IL-17, IL-23, IL-12 
• Chemically drive: Imiquimod (IMQ) 
These models are cheap, straightforward, and fast at inducing clinical phenotypes. The 







Obviously, each psoriasis mouse model possesses its own advantages and 
disadvantages. But none of them can completely resemble the pathological features that 
occur in humans. Thus, the data from animals should be carefully extrapolated to humans. 
Nevertheless, the animal model that is suitable for the study of psoriasis should reflect 
many key histological features of the disease such as acanthosis (uniform elongation of 
the rete ridges), parakeratosis (retention of nuclei in the stratum corneum), hyperkeratosis 
(thickening of the outer layer of skin), microabscesses of inflammatory cells, and scales 
[3]. In addition to these criteria, the model should be reproducible, show similar disease 
mechanisms to cause psoriasis, as well as be responsive to a therapeutic agent that has 
shown efficacy in psoriasis. 
Toward this end, the IMQ mouse model was chosen as a psoriasis model in this 
study. This animal model forms psoriatic like lesions by external immune activation and 
has been increasingly used due to its convenience, cheap, rapid induction, and ability to 
closely resemble human psoriasis. Moreover, the model has been useful for the 











5.3 IMQ mouse model [131] 
IMQ is 1-isobutyl-1H-imidazo(4,5-c)quinolin-4-amine, an imadazoquinoline 
derivative, that was originally developed as a low molecular weight nucleoside analog for 
the induction of IFNs to provide antiviral activity (Fig 5.3) [132]. Due to its small size and 
hydrophobicity, IMQ was suitable to be developed as a topical formulation for the 
treatment of external genital and perianal warts [133]. IMQ-induced skin inflammation 
model is based on the application of a single synthetic innate Ag receptor ligand and does 
not require strong adjuvants like CFA or IFA to activate the immunity leading to the release 
of IL-17. In clinical applications, IMQ is a prescription medication that acts as an immune 
response modifier that activates immune cells via the toll-like receptor (TLR) 7 [13, 134]. 
IMQ is generally used for treating genital warts and a number of skin conditions including 
superficial basal cell carcinoma and actinic keratosis [135]. Topical use of IMQ for several 
weeks can cause psoriasis as a side effect [136]. The induction of cytokines such as 
interferon (IFN)-α, IFN-γ and interleukin (IL)-12 will then promote a type 1 T-helper cell 
(Th1), or cell-mediated immune response [137, 138]. IMQ-treated mouse skin exhibits 
most of the human psoriasis characteristics toward erythema, skin thickening, scaling, 
epidermal alterations (acanthosis, parakeratosis), and neoangiogenesis. Along with the 
respective to inflammatory infiltrate consisting of T cells, neutrophils, DCs, and pDCs. The 
IL23/IL17 pathway is mainly involved in the progression of disease. Therefore, the IMQ 
induced psoriasis model is widely accepted as a reliable preclinical psoriasis model and 
was used for this study. 
 
 
Fig 5.3 Chemical structure of Imiquimod (IMQ), a selective TLR 7 agonist
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5.3.1 Mice and treatment 
C57BL/6 female mice at 8 to 11 weeks old were purchased from Charles River 
Laboratories and maintained in University of Nebraska Medical Center animal facilities in 
accordance with the standards Guide for the Care and Use of Laboratory Animals and the 
Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). All 
animal procedures were approved by the Institutional Animal Care and Use Committee 
(IACUC), University of Nebraska Medical Center, NE.  
Mice received a daily topical dose of 62.5 mg of commercially available IMQ cream 
(5%) on the shaved back for 9 consecutive days. Topical application of IMQ showed 
systemic effects in mice. Mice became ill from day 2 as evidenced by decreased appetite, 
movement, and weight loss of 18%. These effects might reflect a pyrogenic response 
since IMQ application transiently induced high levels of circulating IL-6 in mice [131]. 
Moreover, we also observed a 3-fold increase in spleen mass reflecting the disease 







Fig 5.4 Psoriatic dorsal skin and pH test. Skin thickening, erythema, and scaling are 
observed on gross appearance. The skin became more acidic (yellow to orange color) 


































































Fig 5.5 IMQ-treated dorsal skin mice observation 
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5.3.2 Model observation and evaluation 
5.3.2.1 Histology of psoriatic skin 
Part of psoriatic lesion was harvested, fixed with 10% formalin solution, and 
processed for histological paraffin sectioning. The sections were stained with H&E, CD3, 
CD31, CD68, and Ki-67 to verify the presence of psoriasis features in IMQ-treated mouse 
model. 
Analysis of H&E stained section from IMQ-treated skin showed increased 
epidermal thickening (Acanthosis). Acanthosis was caused by the hyperproliferation of 
keratinocytes as increased numbers of keratinocytes infiltrated the basal layer. Scaling of 
the skin is often an indication of parakeratosis, which is an altered epidermal 
differentiation. Close examination of H&E stained sections of IMQ-treated mice showed 
retention of nuclei in the stratum corneum due to a disturbed epidermal differentiation and 
an absent granular layer. The number of T-cells (CD3+), endothelial blood vessels 
(CD31+), macrophages (CD68+) in dermal region, and proliferating cells (Ki-67) of basal 
keratinocytes were significantly different between healthy and psoriatic groups. The 
proliferative activity of the epidermis, angiogenesis, and inflammation seen in the skin 
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5.3.2.2 Upregulation of TNF-α and CXCR4 in psoriatic mouse skin  
Total RNA was extracted from back skin (isolated after sacrificing the mice) using 
Trizol reagent (Life Technologies, Gaithersburg, MD), according to the manufacturers 
protocol. cDNA was reverse transcribed from 2 ug of RNA using MultiScribe™ reverse 
transcriptase. mRNA level was measured by real-time quantitative PCR analysis using the 
Rotor-Gene Q instrument from QIAGEN (Hilden, Germany). The buffer condition used 
iTaq™ Universal SYBR® Green supermix kit (2x) and 10 μM of each primer. The 
amplification cycle was conducted as follow: initial denaturation at 95 °C for 30 seconds, 
then 40 cycles of denaturation (95 °C) for 5 seconds, and followed by annealing (60 °C) 
for 30 seconds. mRNA level of cytokines were calculated relative to the amount found in 
a control (healthy) sample according to the comparative threshold cycle (Ct) method, and 























































Fig 5.7 Upregulation of TNF-α and CXCR4 in psoriatic mouse skin. 
The IMQ induced changes in cytokine expression and elevated the levels of mRNA 
CXCR4 and TNF-α (Fig 5.7). TNF-α, a pro-inflammatory cytokine, is produced by several 
cell types in inflammatory processes, including macrophages, keratinocytes, Th1 cells, Th 
17 cells and inflammatory DCs [139]. There are evidence that the circulating levels of TNF-
α are elevated in both blood and psoriasis lesions, and correlate with disease severity 
[140]. TNF-α regulates the ability of DCs to activate T cells and induces the expression of 
several cytokines and chemokines. Hence, the inhibition of TNF-α is effective in the 





IN VIVO THERAPEUTIC STUDIES OF TOPICAL CXCR4 POLYMERS IN IMIQUIMOD-
INDUCED PSORIATIC LIKE SKIN MOUSE MODEL 
 
6.1 Introduction 
AMD3100 showed promising results in treating psoriasis-like conditions in IMQ 
mouse models [58]. AMD3100 blocked the signal between CXCR4, expressed on immune 
cells and endothelial cells, and SDF-1 that is secreted by inflamed tissue. Blocking CXCR4 
subsequently reduces inflammatory cascades (induced by T cell activation) and the 
increased number of blood vessels present in psoriatic lesions. Originally, AMD3100 was 
subcutaneously injected, which causes systemic side effects in chronic disease like 
psoriasis. Therefore, topical application of a CXCR4 inhibitor would be a good approach 
to target the disease locally with minimal systemic side effects.  
In the previous chapters, PAMD and PAMD analogs were synthesized and 
analyzed. The in vitro cell studies and ex vivo skin penetration studies were then 
conducted. We observed the CXCR4 reversible properties, biocompatibility, high 
accumulation, and deep penetration of hydrophilic, negatively charged PAMD. These 
findings provided us with strong rationale to test anti-psoriatic efficacy of the polymers in 
vivo. In this chapter, the in vivo therapeutic studies of PAMD were performed and the 
activity was compared with subcutaneous administration of AMD3100 and topical 






6.2 In vivo IMQ-induced psoriatic plaque like model 
The model was developed by Fits et al. [143] and has been utilized by a number 
of investigators in psoriasis studies. Female C57BL/6 mice [144] were purchased from 
Charles River Laboratories at 8 weeks of age and allowed 3 days to acclimate prior to 
starting the experiments. Mice were briefly sedated with isoflurane and the back skin was 
carefully shaved (4 cm2) using an electrical razor [145]. Two days later, a topical dose of 
3.125 mg IMQ active compound or 62.5 mg of IMQ cream was applied daily to the shaved 
back for 5 consecutive days. The mice with inflamed skin were then divided into 5 groups 
(3 mice each): vehicle (water-ethanol 50%, negative control), 1% hydrocortisone (positive 
control), PAMD (topical solution), PAMD.COO- (topical solution), and AMD3100 (S.C.). 
The following treatment doses were given: 1 g/kg/day (PAMD), 10 mg/kg/12h (AMD3100), 
and 100 mg/kg/day (hydrocortisone). The treatment was carried out for another 5 
consecutive days and mice were sacrificed on day 10 using CO2 exposure followed by 
cervical dislocation (Fig 6.1).  
































6.3 Scoring severity of skin inflammation  
To score the severity of skin inflammation, an objective scoring system was used 
based on the clinical Psoriasis Area and Severity Index (PASI). Redness, scaling, and 
thickening were scored independently from 0 to 4, which was described by Armanda et al 
(Fig 6.2) [146]. Skin thickness was measured using digital caliper with the increased 
thickness indicating the extent of the inflammation. The score was determined daily and 













Fig 6.2 Psoriasis scaling. Psoriasis Area and Severity Index (PASI) scoring based on (a) 




6.4 Results and discussion 
Mice were weighed before starting the experiment, during the experiment and prior 
to sacrifice. The spleens from each mouse were removed and weighed immediately 
following sacrifice. The spleen is a sensitive indicator of immune stimulation or depletion. 
The increased spleen mass may demonstrate the increased number of cells in the spleen, 
which may reflect the immune activation and systemic effects. The spleen was harvested 
































































Fig 6.3 Effect of treatment on splenomegaly. 
A significant difference in splenomegaly was observed between healthy and 
psoriatic groups, but there was no difference among the negative (vehicle), positive 
(hydrocortisone), AMD3100 (S.C.), PAMD and PAMD.COO- groups. These results 















































































Fig 6.4 Effect of PAMD treatment on animal body weight, skin thickness and PASI score 
in psoriatic mice. 
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6.4.1 Gross observation 
The topical application of IMQ cream to mouse skin elicits a dermatitis resembling 
psoriasis features, including erythema, scaling, keratinocyte proliferation with acanthosis, 
parakeratosis, and dermal inflammatory infiltrate. Here, decreased body weight was 
observed after the IMQ was applied, but the mice could recover after day 3. The reduction 
of body weight might reflect the systemic response to IMQ, which includes dehydration 
and decreased activity level. 
By judging the PASI score, as expected, the therapeutic efficacy of hydrocortisone 
was more pronounced compared to the rest of the treatment groups. We observed that a 
local treatment with PAMD and PAMD.COO- contributed comparable anti-psoriasis activity 
as subcutaneously injected AMD3100. The PASI scores decreased between from 
hydrocortisone to AMD3100, PAMD, PAMD.COO-, and vehicle. AMD3100 (S.C) showed 
a more rapid onset than PAMD and PAMD.COO- due to the potency of systemic 
administration. PAMD.COO- must be activated in the skin to show its activity, thus requires 
longer onset of action than the other groups. The inflammation observed in the vehicle 
group was as expected (Fig 6.4) [127, 147]. 
 
6.4.2 Histology 
The back skin of mice was collected and fixed in 4% paraformaldehyde. The 
tissues were submitted to the UNMC tissue core facility for paraffin embedding and 
staining with H&E. Additional staining applied was Ki-67, a cellular proliferation marker. A 
light microscope equipped with a computer-controlled digital camera was used to visualize 





Fig 6.5 Representative skin sections of treated mice stained with H&E.  
 
 



























































Fig 6.7 Histological evaluation of skin sections was scaled based on four parameters. 
IMQ induces psoriatic phenotypes such as the thickening of both the epidermal 
and subcutaneous tissue, the thinning of the granular layer along with suprapapillary 
thinning of the epidermis, the retention of nuclei in the stratum corneum, and infiltration of 
inflammatory cells in the skin.  
The topical application of hydrocortisone, PAMD, PAMD.COO-, and 
subcutaneously injected AMD3100 demonstrated relieved inflammation in the IMQ mouse 
model as the accumulative histology scores decreased when compared with the vehicle 
(Fig 6.7). However, the animals did not completely recovered from the disease as 
evidenced by Ki-67 staining. Ki-67 positive staining cells were counted in the basal layer 




6.4.3 Effect of PAMD on skin inflammatory cytokines 
T cells require secondary signals such as interleukins, IFNs and TNF-α to activate 
skin inflammatory cascade. The crosstalk between cytokines can also induce other pro-
inflammatory cytokines production and thus prolong the severity and duration of the 
disease. In this study, we evaluated the in vivo therapeutic response by measuring effect 
of the treatment on mRNA levels of IL-6, IL-1β, TNF-β, and CXCR4 using qRT-PCR.  
IL-1 cytokine family is linked to the innate immunity and the mediator in the initiation 
and maintenance of psoriasis. Changes in the levels of IL-1 occur upon keratinocyte 
differentiation and hyperproliferation and it was markedly increased in psoriasis. IL-1β is 
the most studied member because of its role in mediating local and systemic inflammation. 
IL-1β is produced by monocytes, macrophages, and dendritic cells in response to TLR 
activation [148]. IL-1β is then secreted into the microenvironment and induces the 
expression of adhesion molecule on endothelial cells, resulting in the migration of 
monocytes and neutrophils to inflamed tissue [149, 150]. The inhibition of IL-1β blocked 
Th17 differentiation and reduced psoriasis plaques [150, 151]. 
IL-6 is a multifunctional inflammatory cytokine that is produced by dendritic cells, 
macrophage, monocytes, T cells and keratinocytes in response to a variety of stimuli 
including IL-1 and TNF. IL-6 is expressed in high level in psoriasis and contributed to the 
keratinocyte proliferation, Th17 differentiation, and tissue inflammation. IL-6 helps to 
activate local inflammatory infiltrate (T cells, macrophage, leukocytes), leading to the 
severity of psoriasis [152, 153]. IL-6 also correlates with the inhibition of regulatory T cells 
(Treg) differentiation.  Thus, T memory cells (Tmem) are chronically activated and lead to 




Table 6.1 Primer sequences of mouse genes examined by qRT-PCR 
Target gene Primer sequence 
IL-6 forward ATGGATGCTACCAAACTGGAT 
IL-6 reverse TGAAGGACTCTGGCTTTGTCT 
IL-1β forward CAACCAACAAGTGATATTCTCCATG 
IL-1β reverse GATCCACACTCTCCAGCTGCA 
TNF- α forward GCCCACGTCGTAGCAAACCAC 
TNF- α reverse GCAGGGGCTCTTGACGGCAG 
CXCR4 forward CCTCGCCTTCTTCCACTGTT 
CXCR4 reverse CTGGGCAGAGCTTTTGAACTTG 
GAPDH forward TCCACTGGCGTCTTCAC 





















































































































































































































Fig 6.8 Relative mRNA levels of cytokines in mouse skin treated with different compounds 
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IMQ elicited an elevated mRNA level of TNF-α, IL-6, IL-1β, and CXCR4. mRNA 
levels of TNF-α, IL-1β, and IL-6 cytokines were decreased by AMD3100 (S.C), 
hydrocortisone, PAMD, and PAMD.COO- but were not statistically significant due to the 
small sample size. The decrease in CXCR4 might be the consequence of decreased skin 
inflammation that led to the reduction of immune cells migrating toward CXCR4 ligands 
that are typically produced by inflamed tissue. These results suggested that the 
improvement of psoriasis, determined by PASI score and histological evaluation, related 
to the reduction of multiple inflammatory cytokines (Fig 6.8). These findings need to be 
further validated in a larger group with more signature cytokines of Th1/Th17 (IFN-γ, IL-
17, and IL-23) as well as a variation in dosages and duration of treatment. 
 In summary, all treatment groups reduced the inflammation in the IMQ mouse 
model of psoriasis. Although hydrocortisone, the positive control in this study, showed 
more of an effect, it was not significantly different from the other treatment groups. Topical 
application of PAMD and PAMD.COO- provided similar effects as AMD3100 (S.C), but 
caused no side effects. PAMD and PAMD.COO- showed comparable outcome, the anti-
psoriatic activity of these polymers was not dependent on the penetration amount or depth, 







7.1 Overall conclusion 
Topical delivery of a polymeric CXCR4 inhibitor PAMD was explored as an 
alternative for subcutaneously injected AMD3100 for the management of psoriasis. The 
rate and extent of drug absorption in skin depend on the size, charge and composition of 
the drug delivery system. In these studies, we synthesized two PAMD analogs with 
different charge and hydrophobicity. PAMD and PAMD.COO- are hydrophilic molecules 
but PAMD had positive charge and PAMD.COO- had negative charge. PAMD.OA is a 
lipophilic molecule with positive surface charge. The conjugation with citraconic anhydride 
molecule was selected to make PAMD.COO-. PAMD.COO- exhibited both negative 
surface charge and charge conversion properties. The conversion of PAMD.COO- to 
PAMD occurred in acidic environment and the rate was dependent on time and pH. 
The cellular toxicity was examined in HaCaT human keratinocytes. The unmodified 
PAMD caused cell death more than PAMD.OA and there was no cell killing in PAMD.COO-
. Thus, PAMD.COO- is more biocompatible and potentially will exhibit less skin toxicity 
than PAMD. Skin penetration is important in the development of all topical formulations to 
predict pharmacological effects and improve formulation. The skin penetration was 
performed in Franz diffusion cell for 24 h at physiological conditions. All PAMD polymers 
accumulated more in psoriatic skin when compared with heathy skin, a consequence of 
the compromised barrier function in psoriatic lesions. The negatively charged polymers 
showed the highest skin retention and ability to penetrate into dermis. The penetration 
pathway of polymers was also examined. The positively charged polymers showed 
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features of intracellular transport, while the negatively charged polymers showed evidence 
of intercellular route.  
IMQ-induced psoriasis mouse model was used to investigate the in vivo 
therapeutic efficacy of PAMD polymers in comparison with hydrocortisone and AMD3100. 
Histological examination and cytokine analysis in the skin were performed. We observed 
the reduction of skin inflammation in all treatment groups (decrease PASI score, 
decreased histological psoriatic score, and decreased mRNA level of pro-inflammatory 
cytokines). Interestingly, the topical application of PAMD and PAMD.COO- gave 
comparable effect to AMD3100 (S.C).  
 
7.2 Future studies 
1. Extend to a larger sample size to reduce the variation within a group. 
2. Optimize the dose and treatment duration. 
3. Consider using transgenic mice VEGF-K14 for a stable and long term psoriasis model. 
4. Improve formulation and therapeutic outcome 
• Combination with other anti-psoriatic treatments that offer the possibility of 
synergistic or additive effects. 
• Incorporation into an appropriate base to increase the contact time and improve 
skin homeostasis. 
5. Combination with physical enhancement methods to facilitate the polymer deposition 
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